**RHA® 3**

**CAUTION: FEDERAL LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN OR LICENSED PRACTITIONER.**

**BEFORE USING RHA® 3, PLEASE READ THE FOLLOWING INFORMATION THOROUGHLY**

## DEVICE DESCRIPTION

RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogeneous and biodegradable gel implant. It is produced with sodium Hyaluronic Acid (NaHA) with a concentration of 23 mg/g obtained from bacterial fermentation using the *Streptococcus equi* bacterial strain, crosslinked with 1,4-butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.

## INTENDED USE / INDICATIONS

RHA® 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs), in adults aged 22 years or older.

RHA® 3 is indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness, in adults aged 22 years or older.

## CONTRAINDICATIONS

- RHA® 3 is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.
- RHA® 3 contains trace amounts of gram positive bacterial proteins, and is contraindicated for patients with a history of allergies to such material.
- RHA® 3 should not be used in patients with previous hypersensitivity to local anesthetics of the amide type, such as lidocaine.
- RHA® 3 should not be used in patients with bleeding disorders.

## WARNINGS

- Introduction of product into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. To avoid this:
  - Do not inject into blood vessels
  - Take extra care when injecting soft tissue fillers, inject the product slowly and apply the least amount of pressure necessary.

  Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. If a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure, immediately stop the injection. Patients should receive prompt medical attention and possibly evaluation by an appropriate health care practitioner specialist should an intravascular injection occur.
- Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives), infection or skin injury is present should be deferred until the underlying process has been controlled.
- Treatment site reactions consist mainly of short-term inflammatory symptoms (e.g., swelling, redness, tenderness, or pain) and generally resolve within 14 days. Refer to the ADVERSE EXPERIENCES section for details.
- Inflammatory reaction, anaphylactic reaction, edema, implant migration, acne, blisters, scarring, papules and delayed onset of granulomas have been reported following the use of dermal fillers.

## PRECAUTIONS

- In order to minimize the risks of potential complications, this product should only be used by experienced health care practitioners who have appropriate training in filler injection techniques, and who are knowledgeable about the anatomy at and around the site of injection.
- Health care practitioners are encouraged to discuss all potential risks of soft tissue injection with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.
- The safety and effectiveness for the treatment of anatomic regions other than those described in the INTENDED USE / INDICATIONS section have not been established in controlled clinical studies.
- As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.
- The safety in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.
- The safety for use in sites in the presence of other implants (including permanent implants) has not been studied.
- The safety for use during pregnancy, in breastfeeding females, and in patients under 22 years of age has not been established.
- RHA® 3 should be used with caution in patients on immunosuppressive therapy.
- Bruising or bleeding may occur at RHA® 3 injection sites. RHA® 3 should be used with caution in patients who are using substances that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation).
- Injection of RHA® 3 into patients with a history of previous herpetic eruption may be associated with reactivation of the herpes.
- If laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment with RHA® 3, there is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if RHA® 3 is administered before the skin has healed completely after such a procedure.
- RHA® 3 is to be used as supplied. Modification or use of the product outside the Instructions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.
- RHA® 3 is packaged for single-patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.
- Do not use if package is opened or damaged. The sterility of the product is not guaranteed in the case of failure to comply with this precaution. RHA® 3 is a clear, colorless gel without particulates. In the event the contents of a syringe show signs of separation and/or appears cloudy, do not use the syringe; contact Revance Therapeutics, Inc. 877-3REV-NOW (877-373-8669).
- Failure to comply with the needle attachment instructions could result in needle disengagement and/or product leakage at the Luer-lock and needle hub connection.

## ADVERSE EXPERIENCES

There were two U.S. studies from which safety is summarized. One study was conducted in support of the indication for correction of moderate to severe dynamic wrinkles and folds, such as NLFs using RHA® **3**, and one study was conducted in support of the indication for lip augmentation using RHA® **3**.

### 1. Clinical Evaluation of RHA® 3 into the NLFs

Clinical study TEO-RHA-1302 was a multicenter, controlled, randomized, double-blinded, within-subject (split-face), prospective US study designed to compare the safety of RHA® 3 versus a control treatment for the treatment of moderate to severe nasolabial folds, and demonstrated similar safety profiles. The expected signs and symptoms that occur following the injection of a hyaluronic acid-based dermal filler (i.e., Common Treatment Responses; CTR) were individually assessed by subjects in a preprinted 14-day diary after each injection.

Subjects were asked to rate each CTR as None, Mild, Moderate or Severe:

- Mild: Little discomfort, no effect on daily activities, no medication or make-up required
- Moderate: some discomfort, some effect on daily activities, possibly medication or make-up required
- Severe: Great discomfort, daily activities compromised, very likely medication or make-up required

CTRs by severity and duration are presented respectively, in Table 1 and Table 2.

- The most frequent CTRs were firmness, redness, tenderness, swelling, lumps/bumps, and bruising.
- Proportions of subjects experiencing at least one CTR of each category was similar between RHA® 3 and control treatment.
- More than 60% of the CTRs had resolved by Day 7.
- The majority (more than 88%) of CTRs had resolved by Day 14.
- There were no notable differences between RHA® 3 and control treatment with regard to the small proportion of subjects who reported a severe CTR.
- For the majority of CTRs (more than 84%) experienced by any treatment group (initial treatment or touch-up treatment), the maximal severity reported was “Mild” or “Moderate”.
- On the last day of the diary, nearly all ongoing CTR had improved to mild.

**Table 1. Common Treatment Responses by maximum severity after initial treatment with RHA® 3 and the control device reported in subject 14-day-diary – Safety Population**

| Common Treatment Responses | TOTALS | | RHA® 3 (N[a]=75 NLF) | | | Control Device (N[a]=75 NLF) | | |
|---|---|---|---|---|---|---|---|---|
| | RHA® 3 n[b] % | CTRL[c] n[b] % | Mild n[b] % | Mod[d] n[b] % | Sev[e] n[b] % | Mild n[b] % | Mod[d] n[b] % | Sev[e] n[b] % |
| Bruising | 42 56.0% | 38 50.7% | 20 26.7% | 15 20.0% | 7 9.3% | 12 16.0% | 20 26.7% | 6 8.0% |
| Discoloration | 22 29.3% | 22 29.3% | 7 9.3% | 11 14.7% | 4 5.3% | 10 13.3% | 8 10.7% | 4 5.3% |
| Firmness | 48 64.0% | 45 60.0% | 21 28.0% | 21 28.0% | 6 8.0% | 22 29.3% | 21 28.0% | 2 2.7% |
| Itching | 13 17.3% | 11 14.7% | 7 9.3% | 4 5.3% | 2 2.7% | 5 6.7% | 4 5.3% | 2 2.7% |
| Lumps/Bumps | 49 65.3% | 40 53.3% | 21 28.0% | 21 28.0% | 7 9.3% | 22 29.3% | 14 18.7% | 4 5.3% |
| Pain | 30 40.0% | 23 30.7% | 21 28.0% | 6 8.0% | 3 4.0% | 18 24.0% | 4 5.3% | 1 1.3% |
| Redness | 43 57.3% | 42 56.0% | 26 34.7% | 14 18.7% | 3 4.0% | 26 34.7% | 15 20.0% | 1 1.3% |
| Swelling | 41 54.7% | 38 50.7% | 22 29.3% | 15 20.0% | 4 5.3% | 22 29.3% | 15 20.0% | 1 1.3% |
| Tenderness | 44 58.7% | 37 49.3% | 29 38.7% | 12 16.0% | 3 4.0% | 26 34.7% | 10 13.3% | 1 1.3% |

[a] Number of subjects’ NLF treated with the respective device
[b] Number of subjects’ NLF with any specific Common Treatment Response
[c] CTRL = Control treatment
[d] Mod = Moderate
[e] Sev = Severe

**Table 2. Duration of Common Treatment Responses after initial treatment with RHA® 3 and the control device reported in subject 14-day-diary – Safety Population**

| Common Treatment Responses | RHA® 3 (N[a]=75 NLF) N[b] % | | | | Control Device (N[a]=75 NLF) N[b] % | | | |
|---|---|---|---|---|---|---|---|---|
| Duration[c] | 1-3 Days | 4-7 Days | 8-14 Days | Last Day[d] | 1-3 Days | 4-7 Days | 8-14 Days | Last Day[d] |
| Bruising | 11 14.7% | 19 25.3% | 12 16.0% | 4 5.3% | 11 14.7% | 16 21.3% | 11 14.7% | 1 1.3% |
| Discoloration | 10 13.3% | 6 8.0% | 6 8.0% | 4 5.3% | 13 17.3% | 5 6.7% | 4 5.3% | 3 4.0% |
| Firmness | 18 24.0% | 7 9.3% | 23 30.7% | 9 12.0% | 16 21.3% | 14 18.7% | 15 20.0% | 3 4.0% |
| Itching | 9 12.0% | 4 5.3% | 0 0.0% | 0 0.0% | 8 10.7% | 3 4.0% | 0 0.0% | 0 0.0% |
| Lumps/Bumps | 17 22.7% | 11 14.7% | 21 28.0% | 12 16.0% | 15 20.0% | 13 17.3% | 12 16.0% | 6 8.0% |
| Pain | 21 28.0% | 7 9.3% | 2 2.7% | 0 0.0% | 18 24.0% | 3 4.0% | 2 2.7% | 1 1.3% |
| Redness | 27 36.0% | 9 12.0% | 7 9.3% | 2 2.7% | 27 36.0% | 10 13.3% | 5 6.7% | 2 2.7% |
| Swelling | 18 24.0% | 12 16.0% | 11 14.7% | 5 6.7% | 19 25.3% | 11 14.7% | 8 10.7% | 4 5.3% |
| Tenderness | 17 22.7% | 13 17.3% | 14 18.7% | 5 6.7% | 17 22.7% | 13 17.3% | 7 9.3% | 3 4.0% |

[a] Number of subject NLF treated with the respective device
[b] Number of subject NLF with each specific CTR by maximum duration
[c] Duration refers to number of days cited in the patient diary, irrespective of date of injection
[d] The CTR numbers indicated in the “Last Day” column are also included in the “8-14 Days” column.

An adverse event (AE) was defined as a treatment-related event that was not considered typical in type and/or duration and/or severity. Also, CTRs from the patient’s diary that were recorded on the last day of diary were automatically elevated to the status of adverse event, regardless of severity.

- All treatment-related AEs were mild or moderate in severity.
- All treatment-related AEs experienced by both treatment groups were typical of the expected signs and symptoms observed following an injection of a hyaluronic acid-based dermal filler.
- All treatment-related AEs were temporally associated with a recent device (RHA® 3 or control treatment) injection (no late onset).
- All treatment-related AEs were based on subjects’ diary entries.
- No events were deemed to be a granuloma.
- There were no late onset treatment-related AEs.
- There were no treatment-related serious AEs.

### 2. Clinical Evaluation of RHA® 3 into the lips

The safety of the RHA® 3 indicated for lip augmentation was studied against a control treatment in a multicenter, controlled, randomized, double-blinded, between-subject, prospective U.S. clinical study. Similar safety profiles between RHA® 3 and its comparator were demonstrated.

The expected signs/symptoms that occur following the injection (i.e., CTRs) were captured by subjects in a 30-day diary. Injection sites on

each side of the face were individually assessed by subjects over 30 days following study injections.

CTRs by severity and duration are presented respectively, in Table 3 and Table 4.

- The most frequent CTRs were swelling, lumps/bumps, firmness, tenderness, bruising and redness.
- Proportions of subjects with at least one CTR were similar between RHA®3 and control treatment.
- The majority (84%, 278/329) of CTRs resolved within 14 days.
- There were no notable differences between RHA®3 and control treatment with regard to the proportion of subjects with at least one severe CTR: 22% (31/140) for RHA®3 against 23% (11/47) for the control. The most common CTR reported as severe was swelling. All severe CTRs did not last more than 8 days, except for 1 RHA®3 subject who experienced severe Tenderness and severe Firmness which had a maximum duration of 14 days.
- For most of the diaries with at least one CTR reported, the maximal severity was "Mild" or "Moderate" in both treatment groups (78%, 109/140 for RHA®3 and 77%, 36/47 for the control).
- 19% of the retrieved diaries (37/195) contained at least one CTR on the last day of the 30-day diary: 20% in the RHA®3 group (30/147) against 15% in the control group (7/48). All were mild in severity and not clinically significant. They were all elevated to Treatment-related AEs.

Similar safety profiles were observed after touch-up and retreatment, with no difference between RHA® 3 and control groups.

**Table 3.** Common Treatment Responses by maximum severity after initial treatment with RHA® 3 and the control device reported in subject 30-day diary – Safety Population

| Common Treatment Responses | TOTALS | | RHA® 3 (N[a]=153) | | | Control (N[a]=49) | | |
|---|---|---|---|---|---|---|---|---|
| | RHA® 3 n[b] % | Control n[b] % | Mild n[b] % | Mod[c] n[b] % | Sev[d] n[b] % | Mild n[b] % | Mod[c] n[b] % | Sev[d] n[b] % |
| At least 1 CTR | 140 95.2% | 47 97.9% | 58 41.4% | 51 36.4% | 31 22.1% | 17 36.2% | 19 40.4% | 11 23.4% |
| Bruising | 102 69.4% | 25 52.1% | 51 50.0% | 34 33.3% | 17 16.7% | 18 72.0% | 6 24.0% | 1 4.0% |
| Discoloration | 65 44.2% | 20 41.7% | 39 60.0% | 19 29.2% | 7 10.8% | 12 60.0% | 7 35.0% | 1 5.0% |
| Firmness | 115 78.2% | 38 79.2% | 56 48.7% | 47 40.9% | 12 10.4% | 17 44.7% | 18 47.4% | 3 7.9% |
| Itching | 39 26.5% | 9 18.8% | 31 79.5% | 6 15.4% | 2 5.1% | 7 77.8% | 1 11.1% | 1 11.1% |
| Lumps/Bumps | 115 78.2% | 38 79.2% | 58 50.4% | 46 40.0% | 11 9.6% | 24 63.2% | 10 26.3% | 4 10.5% |
| Pain | 77 52.4% | 31 64.6% | 53 68.8% | 21 27.3% | 3 3.9% | 15 48.4% | 14 45.2% | 2 6.5% |
| Redness | 81 55.1% | 28 58.3% | 49 60.5% | 23 28.4% | 9 11.1% | 17 60.7% | 9 32.1% | 2 7.1% |
| Swelling | 134 91.2% | 47 97.9% | 61 45.5% | 45 33.6% | 28 20.9% | 21 44.7% | 17 36.2% | 9 19.1% |
| Tenderness | 114 77.6% | 38 79.2% | 69 60.5% | 35 30.7% | 10 8.8% | 17 44.7% | 20 52.6% | 1 2.6% |

[a] Number of subjects' Lips treated with the respective device
[b] Number of subjects' Lips with any specific Common Treatment Response
[c] Mod = Moderate
[d] Sev = Severe

**Table 4.** Duration of Common Treatment Responses after initial treatment with RHA® 3 and the control device reported in subject 30-day diary – Safety Population

| CTR Duration[C] | Group (N[a]= subjects | 1-3 Days n[b] % | 4-7 Days n[b] % | 8-14 Days n[b] % | 15-30 Days n[b] % | Last Day n[b] % |
|---|---|---|---|---|---|---|
| At least 1 CTR | RHA®3 (N[a]=153) | 111 75.5% | 100 68.0% | 67 45.6% | 51 34.7% | 30 20.4% |
| | Control (N[a]=49) | 40 83.3% | 33 68.8% | 11 22.9% | 10 20.8% | 7 14.6% |
| Bruising | RHA®3 (N[a]=153) | 29 19.7% | 34 23.1% | 33 22.4% | 6 4.1% | 1 0.7% |
| | Control (N[a]=49) | 12 25.0% | 10 20.8% | 2 4.2% | 1 2.1% | 0 |
| Discoloration | RHA®3 (N[a]=153) | 25 17.0% | 18 12.2% | 15 10.2% | 7 4.8% | 3 2.0% |
| | Control (N[a]=49) | 13 27.1% | 5 10.4% | 2 4.2% | 0 | 0 |
| Firmness | RHA®3 (N[a]=153) | 32 21.8% | 26 17.7% | 27 18.4% | 30 20.4% | 11 7.5% |
| | Control (N[a]=49) | 12 25.0% | 18 37.5% | 4 8.3% | 4 8.3% | 3 6.3% |
| Itching | RHA®3 (N[a]=153) | 22 15.0% | 8 5.4% | 4 2.7% | 5 3.4% | 1 0.7% |
| | Control (N[a]=49) | 5 10.4% | 4 8.3% | 0 | 0 | 0 |
| Lumps /Bumps | RHA®3 (N[a]=153) | 30 20.4% | 23 15.6% | 17 11.6% | 45 30.6% | 27 18.4% |
| | Control (N[a]=49) | 13 27.1% | 14 29.2% | 2 4.2% | 9 18.8% | 7 14.6% |
| Pain | RHA®3 (N[a]=153) | 40 27.2% | 19 12.9% | 10 6.8% | 8 5.4% | 0 |
| | Control (N[a]=49) | 20 41.7% | 9 18.8% | 2 4.2% | 0 | 0 |
| Redness | RHA®3 (N[a]=153) | 42 28.6% | 18 12.2% | 15 10.2% | 6 4.1% | 0 |
| | Control (N[a]=49) | 19 39.6% | 6 12.5% | 3 6.3% | 0 | 0 |
| Swelling | RHA®3 (N[a]=153) | 45 30.6% | 43 29.3% | 32 21.8% | 14 9.5% | 1 0.7% |
| | Control (N[a]=49) | 25 52.1% | 17 35.4% | 2 4.2% | 3 6.3% | 0 |
| Tenderness | RHA®3 (N[a]=153) | 37 25.2% | 32 21.8% | 27 18.4% | 18 12.2% | 3 2.0% |
| | Control (N[a]=49) | 16 33.3% | 13 27.1% | 6 12.5% | 3 6.3% | 1 2.1% |

[a] Number of subjects' Lips treated with the respective device
[b] Number of subjects' lips with each specific CTR by maximum duration
[c] Duration refers to number of days cited in the patient diary, irrespective of date of injection

Lip functionality was assessed at each visit and pre- and post-injection. It included testing:

- Lip function: ability to suck liquid through a straw.
- Lip sensation: ability to feel change of lip sensation with a monofilament and cotton wisp at different locations.
- Lip movement: ability to pronounce specific letters and words.

All subjects were able to perform the tests successfully pre-injection and at every visit thereafter. Less than 10% of subjects had difficulty sucking through a straw, feeling the mono-filament and cotton wisp, or pronouncing certain words, right after injection. All those subjects successfully completed the tests at subsequent visits.

An adverse event (AE) was defined as a treatment-related event that was not considered typical in type and/or duration and/or severity. Also, CTRs from the patient's diary that were recorded on the last day of diary were automatically elevated to the status of adverse event, regardless of severity.

- Both RHA® 3 and control treatment groups presented with similar adverse event (AE) profiles with an overall of 64 subjects experiencing a total of 146 treatment-related AEs after initial treatment and touch-up injections.
- All treatment-related AEs were mild or moderate in severity. No severe treatment-related AEs were reported.
- Most of treatment-related AEs experienced in both treatment groups were typical of the expected signs and symptoms observed following an injection of a hyaluronic acid-based dermal filler, such as: injection site mass, injection site swelling and injection site

induration. Other reported treatment-related AEs such as headache, or pruritus are less typical but not unexpected following a dermal filler injection.

- Most of treatment-related AEs were based on subjects' diary entries (CTRs): 75% (81/108) were either a CTR, or listed as Others, or from the list of pre-identified AEs on the diary and 25% (27/108) were identified by the TI
- Most treatment-related AEs (79%, 85/108) resolved within 30 days and the proportion of subjects with reported treatment related AE was similar across the 2 treatment groups. The duration of treatment-related AEs varied from 1 to 90 days, except for 11 treatment-related AEs (with 9 of them started during the retreatment period) that were still ongoing at the end of the study (i.e., one month after retreatment). These 11 treatment-related AEs were all the typical and expected signs and symptoms observed following the injection of a dermal filler (8 Lumps/Bumps, 1 swelling, 2 firmness). All of them were mild in severity, except one moderate Lumps/Bumps, that resolved one month after injection.
- There were no treatment-related serious AEs.
- One AE of Special Interest (AESI) was reported. The subject received RHA® 3 and developed an event of Vision blurred with mild severity, the same day of the injection. The event was assessed as Unlikely related to the study treatment or the study procedure and did not motivate referral to an eye specialist. No concomitant medications were reported as being used to treat this event. The event resolved without sequelae one day later.
- No events were deemed to be a granuloma or delayed inflammatory response.
- There were no late onset treatment-related AEs.

Safety profile by Fitzpatrick skin type and ethnicity was not different. Rates of treatment-related AEs may vary according to age group without any trend identified.

There were no reported cases of scarring, keloid formation or hyperpigmentation.

**3. Post-marketing Surveillance**

The following adverse events were reported as part of post-marketing surveillance on the use of RHA® 3 worldwide with a prevalence equal or superior to one occurrence for 100,000 syringes: Injection site masses (lumps and bumps), skin swelling, erythema, skin induration, skin edema, vascular complication (such as vessel compression/occlusion), inflammatory reaction, pain, allergic reaction and ecchymosis.

Additionally, other less frequent adverse reactions have also been reported, and includes implant migration, granuloma, dermatitis, skin infection, blister, necrosis, fibrosis, pruritus, abscess, overcorrection, skin discoloration/Tyndall effect, telangiectasia, tenderness, urticaria, anaphylactic reaction, injection site cellulitis, influenza-like illness, keloid scarring, overcorrection, numbness, pigmentation disorder, pustules, papules, paresthesia, nerve damage, numbness, visual impairment, neuralgia, wrinkles, hyperthermia, headache, hemorrhage, herpes outbreaks, injection site movement impairment, dry skin, chapped lips, scabs, puffy skin, dizziness.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

In many cases the symptoms resolved without any treatment. Reported treatments included the use of (in alphabetical order): analgesics, antibiotics, antihistamines, anti-inflammatories, anti-viral, corticosteroids, drainage, excision, implant dissolution (hyaluronidase), incision, massage and vasodilators. Final resolution varies from ongoing to a total resolution of the symptoms with or without sequelae.

**CLINICAL TRIALS**

**TEO-RHA-1302 - RHA® 3 INTO THE NLFs - CLINICAL STUDY**

The long-term safety and effectiveness of RHA® 3 in the correction of moderate to severe facial wrinkles and folds were evaluated in a US pivotal clinical study described hereafter.

**1. Pivotal Study Design**

A controlled, randomized, double-blinded, within-subject (split-face), multicenter, prospective pivotal clinical study was conducted to evaluate the clinical safety and effectiveness of RHA® 3.

Subjects were randomly assigned to receive RHA® 3 and a control treatment in mid-to-deep dermis for the treatment of moderate to severe nasolabial folds, or to a non-treatment group. The side of the face for each device injected was assigned randomly.

If deemed necessary by the Treating Investigator, additional NLF correction was performed after 2 weeks (touch-up), with the same study device used for initial treatment.

The follow-up period consisted of safety and effectiveness follow-up visits at 4, 12, 24, 36, 52, and 64 weeks after the last treatment.

Subjects were eligible for optional retreatment if necessary at Weeks 24 or 36. Subjects were also offered retreatment at Week 52 or Week 64, and were then followed for 1 month after retreatment or until all Adverse Events (AEs) resolve. Retreatment on either side was provided using RHA® 3 (the control treatment was not used).

Subjects randomized to the "no treatment" control group did not receive treatment.

**2. Study Endpoints**

The primary effectiveness endpoint was the analysis of non-inferiority of RHA® 3 versus the control treatment, in terms of change from pre-injection to 24 weeks after injection, as measured by a Blinded Live Evaluator (BLE) using a proprietary and validated 5-grade scale for scoring the severity of nasolabial folds, NLF-WSRS (which for the purposes of this document will be referred to as Wrinkle Severity Rating Scale (NLF-WSRS) score).

Secondary effectiveness endpoints included rates of responders (≥ 1 grade difference from pre-treatment on the NLF-WSRS), as measured by the BLE (see data in Figure 1), Global Aesthetic Improvement (GAI), as assessed by the subject and by the BLE, impact and effectiveness of study treatment procedures from the subjects' perspective as assessed by the nasolabial fold domain of the FACE-Q©, and subject satisfaction.

Safety endpoints was evaluated throughout the study, with a 14-day subject diary capturing post-injection signs/symptoms following every study injection, and AE assessments at each visit, and included self-assessment of injection site pain by the subject using a 100mm Visual Analog Scale.

**3. Demographics**

A total of 74 subjects (26 to 77 years old) were allocated to RHA® 3 and control treatment, and 26 were allocated to untreated controls. 74

subjects were included in the intention-to-treat (ITT) population. Subjects' demographics are presented in Table 5.

**Table 5. Demographics**

| Number / % of subjects | RHA® 3 versus Control Device N[a]=74 | |
|---|---|---|
| **Age** | | |
| Mean (SD) | 55.7 | (9.4) |
| min max | 26 | 77 |
| **Gender** | | |
| Female | 68 | 91.9% |
| Male | 6 | 8.1% |
| **Race** | | |
| Caucasian | 62 | 83.8% |
| Black | 7 | 9.5% |
| Am.Indian/N. Alask. | 0 | 0.0% |
| N. Hawaiian/P. Isl. | 0 | 0.0% |
| Asian | 0 | 0.0% |
| Other | 5 | 6.8% |
| **Ethnicity** | | |
| Hispanic/Latino | 21 | 28.4% |
| Not Hispanic/Latino | 53 | 71.6% |
| **Fitzpatrick Skin Phototype** | | |
| I | 4 | 5.4% |
| II | 21 | 28.4% |
| III | 19 | 25.7% |
| IV | 20 | 27.0% |
| V | 7 | 9.5% |
| VI | 3 | 4.1% |

[a] Number of subjects in the ITT populations

### 4. Treatment Characteristics

The study protocol allowed a maximum of 3.0 ml in a single NLF per treatment session. The overall total median volume of RHA® 3 injected to achieve optimal correction results was 1.4 ml. The proportion of subjects who received touch-up treatment with RHA® 3 at Week 2 was 67.6%.

In general, a linear threading or fan-like technique, or combination, was used for 90.3% of the subjects treated with RHA® 3.

### 5. Effectiveness Results

The primary effectiveness endpoint was met for RHA® 3. The primary effectiveness endpoint was the aesthetic improvement from pre-injection of the NLF treated with RHA® 3 compared to the improvement from pre-injection of the NLF treated with the control treatment, as assessed (using the Nasolabial Folds Wrinkle Severity Rating Scale NLF-WSRS) by the BLE at 24 weeks after baseline; results are presented in Table 6.

**Table 6. Wrinkle Severity Rating Scale scores assessed by a Blinded Live Evaluator throughout the study**

| | | RHA® 3 | | Control Device | |
|---|---|---|---|---|---|
| | n[a] | NLF-WSRS score[b] | NLF-WSRS Improvement[c] | NLF-WSRS score[b] | NLF-WSRS Improvement[c] |
| Pre-treatment[d] | 62 | 3.39 | - | 3.39 | - |
| Week 24 | 62 | 2.06 | 1.32 | 2.16 | 1.23 |
| Week 36 | 58 | 2.36 | 1.03 | 2.41 | 0.98 |
| Week 52 | 56 | 2.45 | 0.91 | 2.54 | 0.82 |
| Week 64 | 47 | 2.47 | 0.91 | 2.55 | 0.83 |

[a] Number of subjects in the PP populations at the respective follow-up visits
[b] Mean NLF-Wrinkle Severity Rating Scale score (higher scores mean deepest wrinkles)
[c] Mean NLF-Wrinkle Severity Rating Scale improvement from pre-treatment (higher scores mean more improvement from pre-treatment)
[d] Primary effectiveness endpoint

The results demonstrated that non-inferiority to the control was achieved for RHA® 3 at 24 weeks for the treatment of NLFs. Results also showed that RHA® 3 was not inferior to the control treatment at all study visits.

Throughout the follow-up period, the aesthetic improvement of the RHA 3 treated NLF continued to be clinically significant (≥ 1 grade difference from pre-treatment on the NLF-WSRS) for more than 78% of the subjects at 64 weeks after initial treatment (Figure 1).

**Figure 1. Proportion of responders on the Wrinkle Severity Rating Scale measured by a Blinded Live Evaluator for RHA® 3 and the Control Device**




| | Week 24 | Week 36 | Week 52 | Week 64 |
|---|---|---|---|---|
| RHA® 3 | 91.9% | 82.8% | 75.0% | 78.7% |
| Control Device | 88.7% | 79.3% | 69.6% | 72.3% |

PP populations at the respective follow-up visits
Rate of responders: ≥ 1 grade difference from pre-treatment on the WSRS

On the Global Aesthetic Improvement (GAI) scale, more than 81% of the subjects and the BLE reported that the NLF treated with RHA® 3 was improved or very much improved from week 24 to week 64. The subjects consistently reported improvement up to 64 weeks based on the NLF module of the FACE-Q© questionnaire with the mean score improving from 29 to more than 63 throughout the follow-up period. More than 90% of the subjects reported to be satisfied or very satisfied 24 weeks after initial treatment and the rate of satisfaction remained at more than 82% at 64 weeks (the scale grades were: very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, or very dissatisfied).

More than 77% of the subjects received repeat treatment. The effectiveness and safety profiles after repeat treatment were similar to that after initial treatment.

## TEO-RHA-1806 – RHA® 3 into the lips - CLINICAL STUDY

The safety and effectiveness of the RHA® 3 indicated for lip augmentation were evaluated in comparison to a control in a U.S. pivotal clinical study described hereafter.

### 1. Pivotal Study Design

A prospective, double-blinded, randomized, controlled, between-subject, multicenter clinical study was conducted to evaluate the clinical safety and effectiveness of RHA® 3 versus control for injection into the lips (vermilion body, vermilion border, and oral commissures) for lip augmentation.

A total of 202 subjects were randomized and underwent treatment with either RHA® 3 (N = 153) or control (N = 49) in the vermilion border, vermilion body and oral commissure for the lip augmentation and lip fullness. If deemed necessary to achieve optimal correction, additional lip correction was performed after 4 weeks (touch-up), with the same study device used for initial treatment.
The follow-up period consisted of safety and effectiveness follow-up visits at 4, 8, 12, 24, 36, and 52 weeks after the last treatment.

Subjects were eligible for optional retreatment if necessary at Weeks 36 or 52, and were then followed for 1 month after retreatment or until all Adverse Events (AEs) resolved or TI determines that follow-up is no longer necessary. Retreatment was provided using RHA® 3 (the control device was not used).

**2. Study Endpoints**

The primary effectiveness endpoint was the analysis of non-inferiority of RHA® 3 versus control in terms of change from Baseline (pre-injection) 12 weeks after injection, as measured by a Blinded Live Evaluator (BLE) using the proprietary and validated 5-grade Teoxane Lip Fulness Scale (TLFS). The co-primary endpoint was the proportion of responders with a ≥1-grade point increase on the TLFS at 12 weeks when compared to pretreatment, which should be ≥ 70%.

Secondary effectiveness endpoints included TLFS change from Baseline and rates of responders, as assessed by the BLE at each study visits (see data in Table 8 and Figure 2), Global Aesthetic Improvement (GAI), as assessed by the subject, and by the BLE, impact and effectiveness of study treatment procedures from the subjects' perspective as assessed by the lip domain and satisfaction of the outcome module of the FACE-Q©, and subject satisfaction.

Safety endpoints was evaluated throughout the study, with a 30-day subject diary capturing post-injection signs/symptoms following every study injection, and AE assessments and lip functionality at each visit, and included self-assessment of injection site pain by the subject using a 100mm Visual Analog Scale. Safety endpoints also included assessment of visual disturbances before and after injection and at each visit.

**3. Demographics**

A total of 202 subjects (22 to 76 years old) were enrolled and included in the Safety population with 153 subjects allocated to RHA® 3 treatment, and 49 allocated to the control treatment. Subjects' demographics are presented in Table 7. A total of 181 subjects were enrolled and included in the mITT population, with 137 subjects allocated to RHA® 3 treatment, and 44 allocated to the control treatment. The mITT population consisted of all enrolled subjects who received treatment and had at least one post-Baseline primary effectiveness visit, excluding subjects with high TLFS grades at Baseline TLFS (a few subjects with FST V and VI to be followed for safety only).

**Table 7. Demographics**

| Number / % of subjects | **RHA® 3** N[a]=153 | **Control** N[a]=49 | **Total** N[a]=202 |
|---|---|---|---|
| **Age** | | | |
| Mean (SD) | 48.8 (13.19) | 48.5 (11.69) | 48.7 (12.82) |
| min max | 22, 76 | 24, 68 | 22, 76 |
| **Gender** | | | |
| Female | 151 (98.7%) | 48 (98.0%) | 199 (98.5%) |
| Male | 2 (1.3%) | 1 (2.0%) | 3 (1.5%) |
| **Race** | | | |
| Am. Indian/N. Alask. | 2 (1.3%) | 1 (2.0%) | 3 (1.5%) |
| Asian | 4 (2.6%) | 1 (2.0%) | 5 (2.5%) |
| Black or African American | 15 (9.8%) | 2 (4.1%) | 17 (8.4%) |
| N. Hawaiian/P. Isl. | 2 (1.3%) | 0 | 2 (1.0%) |
| White | 130 (85.0%) | 45 (91.8%) | 175 (86.6%) |
| **Ethnicity** | | | |
| Hispanic/Latino | 32 (20.9%) | 13 (26.5%) | 45 (22.3%) |
| Not Hispanic/Latino | 118 (77.1%) | 35 (71.4%) | 153 (75.7%) |
| Not available | 3 (2.0%) | 1 (2.0%) | 4 (2.0%) |
| **Fitzpatrick Skin Phototype** | | | |
| **I-III** | **114 (74.5%)** | **35 (71.5%)** | **149 (73.8%)** |
| I | 10 (6.5%) | 7 (14.3%) | 17 (8.4%) |
| II | 46 (30.1%) | 9 (18.4%) | 55 (27.2%) |
| III | 58 (37.9%) | 19 (38.8%) | 77 (38.2%) |
| **IV-VI** | **39 (25.5%)** | **14 (28.6%)** | **53 (26.2%)** |
| IV | 22 (14.4%) | 10 (20.4%) | 32 (15.8%) |
| V | 10 (6.5%) | 3 (6.1%) | 13 (6.4%) |
| VI | 7 (4.6%) | 1 (2.0%) | 8 (4.0%) |

[a] Number of subjects in the safety populations

**4. Treatment Characteristics**

The study protocol allowed a maximum of 1.5 ml per lip at each treatment session. The overall total mean volume of RHA® 3 injected to achieve optimal correction (OCR) (initial + touch-up) was 1.78±0.64 ml. Injection volumes into the lips tended to be lower after retreatment, with total mean injection volume being 1.03±0.45 ml after retreatment. Similar mean injection volumes were used in subjects treated with the control device: 1.95±0.73 ml to achieve OCR and 1.03±0.41 ml after retreatment.

The proportion of subjects who received touch-up treatment at Week 4 was lower with RHA® 3 (58.2%, 89/153) than with control (73.5%, 36/49).

In general, a linear threading, either as a stand-alone technique or in combination with other techniques such as multiple punctate pools or fan like injection, was used for the vast majority of subjects in both treatment groups.

**5. Effectiveness Results**

The primary effectiveness endpoint was the fullness improvement from pre-injection of the lips treated with RHA® 3 compared to the improvement from pre-injection of the lip treated with the control treatment, using the TLFS, as assessed by the BLE at 12 weeks; results are presented in Table 8. Table 9 shows the number of responders and the responder rate as assessed by the BLE 12 weeks after last treatment based on the TLFS grade at Baseline 1, 2 and/or 3.

**Table 8. TLFS Grade Change from Baseline as assessed by the BLE**

| | **RHA® 3 (N=137)** | | **Control (N=44)** | |
|---|---|---|---|---|
| | Mean TLFS score (SD) | Mean TLFS change from Baseline (SD) | Mean TLFS score (SD) | Mean TLFS change from Baseline (SD) |
| Baseline | 2.4 (0.62) | - | 2.3 (0.60) | - |
| **Week 12[a,b]** | 3.4 (0.61) | 1.0 (0.65) | 3.1 (0.65) | 0.8 (0.70) |
| Week 24 | 3.3 (0.75) | 0.8 (0.64) | 2.8 (0.69) | 0.5 (0.63) |
| Week 36 | 3.1 (0.78) | 0.7 (0.65) | 2.8 (0.73) | 0.5 (0.63) |
| Week 52 | 3.0 (0.75) | 0.5 (0.64) | 2.5 (0.67) | 0.1 (0.63) |

[a] Primary effectiveness endpoint

[b] Estimate of difference in means RHA3 – control is 0.19 (-0.03, -0.42) calculated by Bootstrap estimate using 1000 samples.

mITT population

**Table 9. TLFS responder rate (BLE) at Week 12 – mITT Population**

| | **RHA® 3** | **Control** |
|---|---|---|
| **Baseline TLFS grades 1, 2 & 3** | | |
| N | 137 | 44 |
| # of responders (%) [95% CI] | 107 (78.1%) [70.5 - 84.2%] | 29 (65.9%) [51.1 - 78.1%] |
| **Baseline TLFS grades 1 & 2** | | |
| N | 68 | 27 |
| # of responders (%) [95% CI] | 64 (94.1%) [85.8-97.7%] | 24 (88.9%) [71.9-96.1%] |
| **Baseline TLFS grade 3** | | |
| N | 69 | 17 |
| # of responders (%) [95% CI] | 43 (62.3%) [50.5-72.8%] | 5 (29.4%) [13.3-53.1%] |

mITT population

The results demonstrated that non-inferiority to the control in terms of mean TLFS change from baseline was achieved for RHA® 3 at 12 weeks for lip augmentation. However, for the co-primary endpoint, the responder rate for the control group did not meet the performance goal of 70%.

Throughout the follow-up period, the aesthetic improvement of the RHA 3 continued to be clinically significant (≥ 1 grade difference from pre-treatment on the TLFS) for 61% (81/132) of the subjects at 36 weeks after last treatment, and for 48% (38/79) at 52 weeks after last treatment (Figure 2).

**Figure 2. Proportion of responders on the TLFS measured by the BLE for RHA® 3 and the Control Device**




On the Global Aesthetic Improvement (GAI) scale, more than 73% (99%, 134/135 at 12 weeks, 92%, 122/132 at 24 weeks, 86%, 113/132 at 36 weeks and 73%, 58/79 at 52 weeks) of the subjects and the BLE reported that the lips treated with RHA® 3 was improved or very much improved from week 12 to week 52. GAIS responder rate was similar at Week 12 between RHA®3 and control as assessed by BLE, and GAIS responder rates in the RHA3 group are higher than the GAIS responder rates in the control group at all subsequent visits (24, 36 and 52 weeks after last treatment; Figure 3).

**Figure 3. GAIS through 1 year as assessed by the BLE**




The subjects treated with RHA® 3 consistently reported improvement up to 52 weeks based on the *Satisfaction with lips* module of the FACE-Q© questionnaire with the mean score improving from Baseline by 51 points at Week 12, to more than 36 points throughout the follow-up period (46 at Week 24, 41 at Week 36 and 36 at Week 52). Similar results were found with the *Satisfaction with outcomes* module of the FACE-Q© questionnaire.

84% (113/135) of the subjects reported to be satisfied or very satisfied 12 weeks after treatment and the rate of satisfaction was 83% (67/81) at 52 weeks (the scale grades were: very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, or very dissatisfied).

59% (90/153) of the subjects received repeat treatment. The effectiveness and safety profiles after repeat treatment were similar to that after initial treatment and touch-up.

## DIRECTIONS FOR ASSEMBLY OF THE NEEDLE TO THE SYRINGE

1. Remove the stopper from the syringe by pulling it off.



2. Insert the screw thread of the needle firmly into the syringe end-piece.



3. Screw the needle clockwise, while maintaining slight pressure between the needle and the syringe.



4. Continue screwing until the edge of the cap of the needle contacts the body of the syringe. There must be no space between these two parts. Failure to follow this instruction means that the needle could be ejected and/or leak at the Luer-lock.




5. Remove the needle's protective cap by pulling it firmly with one hand while holding the body of the syringe with the other.



## PRE-TREATMENT GUIDELINES

- Prior to treatment, the patient should avoid taking medications or supplements which thin the blood (e.g., aspirin, nonsteroidal anti-inflammatory medications, St. John's Wort, or high doses of

Vitamin E supplements) as these agents may increase bruising and bleeding at the injection site.

- Before starting treatment, a complete medical history should be taken from the patient and the patient should be counseled on appropriate indications, risks, and should be informed about the expected treatment results, and expected responses. The patient should be advised of the necessary precautions before commencing the procedure.
- Prior to treatment with RHA® 3 the patient should be assessed for appropriate anesthetic treatment for managing comfort (e.g., topical anesthetic, local or nerve block). The patient's face should be washed with soap and water and dried with a clean towel. Cleanse the area to be treated with alcohol or another suitable antiseptic solution.
- Sterile gloves are recommended while injecting RHA® 3.
- Before injecting, prime the needle by carefully pressing the syringe plunger until a small droplet of the gel is visible at the tip of the needle.

**INJECTION TECHNIQUES**

- RHA® 3 is administered by using a thin gauge needle (27 G x ½"). For the treatment of NLFs, the needle is inserted into the mid-to-deep dermis at an approximate angle of 15° to 30° parallel to the length of the wrinkle or fold. For lip augmentation, RHA® 3 is injected into the lip mucosa and/or mid to deep dermis as appropriate.
- RHA® 3 can be injected by a number of different techniques that depend on the injector's experience and preference, and patient characteristics. The techniques may include:

**A. Serial puncture:** consists of multiple injections, evenly and closely spaced all along wrinkles or folds. This technique is considered to be more precise, but may result in more discomfort for the patient due to the number of punctures.



**B. Linear threading:** the needle is fully introduced in the wrinkle or the fold, and the product is injected along the line, as a "thread", while withdrawing (retrograde) or pushing (antegrade) the needle.



**C. Fanning technique:** the needle is introduced as for the *Linear threading technique*, and the product is injected along several closely spaced lines, by changing the direction of the needle, all using the same puncture site (the needle is not withdrawn).




- RHA® 3 is injected slowly into the mid-to-deep dermis or into the lip mucosa. If the injection is made too deeply, i.e. into sub-cutaneous tissue, the correction may not be as expected. It is possible to tell when an injection is being made too deeply because subcutaneous tissue does not offer any resistance to product injection, unlike the dermis.
- If the color of the needle can be seen through the skin during injection, this means that the injection is too superficial. This should be avoided as the results of the correction could be irregular.
- The injection should be stopped before pulling the syringe out of the skin, to prevent product from leaking out, or product misplacement (too superficially in the skin).
- The volume to be injected depends on the corrections to be performed, but it is important to not overcorrect. Based on the US clinical study, patients should be limited to 6.0ml per patient per treatment session in wrinkles and folds such as NLFs, and should not exceed 1.5ml per upper lip and 1.5 ml per lower lip per treatment session The safety of injecting greater amounts has not been established.
- If blanching is observed (e.g., the overlying skin turns a whitish color), the injection should be stopped immediately and the area massaged until it returns to a normal color. Blanching may represent a vessel occlusion. If normal skin coloring does not return, do not continue with the injection. Treat in accordance with American Society for Dermatologic Surgery guidelines, which include hyaluronidase injection.
- If the wrinkles or lips need further treatment with RHA® 3, the same procedure should be repeated until a satisfactory result is obtained.

**POST-TREATMENT GUIDELINES**

- When the injection is completed, the treated site may be gently massaged so that it conforms to the contour of the surrounding tissues. If an overcorrection has occurred, massage the area firmly between your fingers or against an underlying area to obtain optimal results.
- If the treated area is swollen immediately after the injection, an ice pack may be applied to the site for a short period (e.g., 5-10 minutes). Ice should be used with caution if the area is still numb from anesthetic to avoid thermal injury.
- After use, syringes may be potential biohazards. Follow national, local, or institutional guidelines for use and disposal of medical biohazard devices. Obtain prompt medical attention if injury occurs.

**STERILE NEEDLES**

- After use, needles are potential biohazards. Follow national, local, or institutional guidelines for use and disposal of medical sharp devices (e.g. discard uncapped needles in approved sharps containers).
- Disposal should be in accordance with accepted medical practice

and applicable local, State and Federal requirements.

- To help avoid needle breakage, do not attempt to straighten a bent needle. Discard it and complete the procedure with a replacement needle.
- Do not recap needles. Recapping by hand is a hazardous practice and should be avoided.
- RHA® 3 is provided with 2 needles that do not contain engineered injury protection. Administration of RHA® 3 requires direct visualization and complete and gradual insertion of the needle making engineered protection devices not feasible. To avoid needle stick injury and sharp exposure, take care to inject in appropriate conditions.
- Obtain prompt medical attention if injury with used needle occurs.

## PATIENT INSTRUCTIONS

Patient information brochure is available on request, or via the website www.revance.com.
It is recommended that the following information be shared with patients:

- Patients should be advised not to wear make-up during 12 hours following injection.
- Patient should be advised not to take high-dose Vitamin E, aspirin, anti-inflammatories or anti-coagulants during the week prior to the injection. Patients must not discontinue such treatment without talking with their prescribing physician.
- Patients should minimize exposure of the treated area to excessive sun, UV lamp exposure and extreme temperatures (e.g. cold weather, sauna) at least within the first 24 hours, or until initial swelling and redness has resolved. Exposure to any of the above may cause/exacerbate and/or extend the duration of temporary redness, swelling, and/or itching at the treatment sites.
- Patients should notify the injector if any of the following occurs:
  - Changes in vision
  - Unusual pain during or shortly after treatment
  - Significant pain away from the injection site
  - Signs of a stroke
  - Any redness and/or visible swelling that lasts for more than a week
  - Any side effect other than those described above or that occur weeks or months after injection
- Adverse reactions should be reported to Revance Therapeutics, Inc at 877-3REV-NOW (877-373-8669) and to Medical-us@teoxane.com.

## HOW SUPPLIED

RHA® 3 is supplied in individual blisters containing a 1ml treatment syringe with two 27 G x ½" needles as indicated on the carton.

The content of the syringe is sterile and non-pyrogenic. Do not resterilize. Do not use if package is opened or damaged.

Each syringe is packaged into a blister with two unique device identifier traceability labels.

## SHELF-LIFE AND STORAGE

RHA® 3 must be used prior to the expiration date printed on the package.

Store at room temperature (up to 25°C/77°F). Do not expose to direct sunlight. DO NOT FREEZE. Do not store partially used syringes.

RxOnly

**Manufactured by:**

TEOXANE S.A.
Rue de Lyon, 105
CH 1203 Geneva
(Switzerland)

**Distributed by:**

Revance Therapeutics, Inc.
1222 Demonbreun Street,
Suite 2000
Nashville, Tennessee 37203



## SYMBOLS

 Manufacturer's name and address

 Catalog number

 Lot / batch number

 Expiration date (YYYY-MM-DD)

 Consult Instructions for use

 Single use only

 Sterilized using steam

 Do not use if the package is damaged

RxOnly Caution: Federal law restricts this device to sale by or on the order of a physician or licensed practitioner